Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2

  1. Shojiro Haji
  2. Taiki Ito
  3. Carla Guenther
  4. Miyako Nakano
  5. Takashi Shimizu
  6. Daiki Mori
  7. Yasunori Chiba
  8. Masato Tanaka
  9. Sushil K Mishra
  10. Janet A Willment
  11. Gordon D Brown
  12. Masamichi Nagae  Is a corresponding author
  13. Sho Yamasaki  Is a corresponding author
  1. Kyushu University, Japan
  2. Osaka University, Japan
  3. Hiroshima University, Japan
  4. Centre National de la Recherche Scientifique, France
  5. National Institute of Advanced Industrial Science and Technology, Japan
  6. Tokyo University of Pharmacy and Life Sciences, Japan
  7. University of Mississippi, United States
  8. University of Exeter, United Kingdom

Abstract

C-type lectin receptors (CLRs) elicit immune responses upon recognition of glycoconjugates present on pathogens and self-components. While Dectin-1 is the best-characterized CLR recognizing b-glucan on pathogens, the endogenous targets of Dectin-1 are not fully understood. Herein, we report that human Dectin-1 is a ligand for CLEC-2, another CLR expressed on platelets. Biochemical analyses revealed that Dectin-1 is a mucin-like protein as its stalk region is highly O-glycosylated. A sialylated core 1 glycan attached to the EDxxT motif of human Dectin-1, which is absent in mouse Dectin-1, provides a ligand moiety for CLEC-2. Strikingly, the expression of human Dectin-1 in mice rescued the lethality and lymphatic defect resulting from a deficiency of Podoplanin, a known CLEC-2 ligand. This finding is the first example of an innate immune receptor also functioning as a physiological ligand to regulate ontogeny upon glycosylation.

Data availability

Sequencing data have been deposited in GEO under accession code GSE196049.

The following data sets were generated

Article and author information

Author details

  1. Shojiro Haji

    Department of Molecular Immunology, Kyushu University, Fukuoka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  2. Taiki Ito

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  3. Carla Guenther

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7915-1028
  4. Miyako Nakano

    Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Takashi Shimizu

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  6. Daiki Mori

    Centre National de la Recherche Scientifique, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Yasunori Chiba

    Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan
    Competing interests
    The authors declare that no competing interests exist.
  8. Masato Tanaka

    Laboratory of Immune Regulation School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Competing interests
    The authors declare that no competing interests exist.
  9. Sushil K Mishra

    Glycoscience Center of Research Excellence, University of Mississippi, Mississippi, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3080-9754
  10. Janet A Willment

    Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7040-0857
  11. Gordon D Brown

    Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Masamichi Nagae

    Department of Molecular Immunology, Osaka University, Osaka, Japan
    For correspondence
    mnagae@biken.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5470-3807
  13. Sho Yamasaki

    Department of Molecular Immunology, Osaka University, Osaka, Japan
    For correspondence
    yamasaki@biken.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5184-6917

Funding

Japan Society for the Promotion of Science (20H00505)

  • Sho Yamasaki

Japan Society for the Promotion of Science (20K06575)

  • Masamichi Nagae

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal protocols were approved by the committee of Ethics on Animal Experiment and Research Institute for Microbial Diseases, Osaka University (Permit number: Biken-AP-R03-17-0).

Human subjects: All human subjects research was approved by the Institutional Review Board of the Research Institute for Microbial Diseases, Osaka University. Informed consent and consent to publish were obtained from all individuals donating venous blood. Consent documents and procedures were approved by the Institutional Review Board of the Research Institute for Microbial Diseases, Osaka University (Permit number 29-12).

Reviewing Editor

  1. Simon Yona, The Hebrew University of Jerusalem, Israel

Publication history

  1. Received: August 28, 2022
  2. Preprint posted: September 4, 2022 (view preprint)
  3. Accepted: December 7, 2022
  4. Accepted Manuscript published: December 8, 2022 (version 1)
  5. Version of Record published: December 23, 2022 (version 2)

Copyright

© 2022, Haji et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 585
    Page views
  • 141
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shojiro Haji
  2. Taiki Ito
  3. Carla Guenther
  4. Miyako Nakano
  5. Takashi Shimizu
  6. Daiki Mori
  7. Yasunori Chiba
  8. Masato Tanaka
  9. Sushil K Mishra
  10. Janet A Willment
  11. Gordon D Brown
  12. Masamichi Nagae
  13. Sho Yamasaki
(2022)
Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2
eLife 11:e83037.
https://doi.org/10.7554/eLife.83037

Further reading

    1. Immunology and Inflammation
    Warren Anderson, Fariba Barahmand-pour-Whitman ... David J Rawlings
    Research Article

    A genetic variant in the gene PTPN22 (R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited (620W), non-risk edited (620R) or knock out T cells from the same donor. PTPN22 risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked PTPN22 KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to PTPN22 non-risk T cells. Together, these findings suggest that, in primary human T cells, PTPN22 rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.

    1. Epidemiology and Global Health
    2. Immunology and Inflammation
    Zaki A Sherif, Christian R Gomez ... RECOVER Mechanistic Pathway Task Force
    Review Article

    COVID-19, with persistent and new onset of symptoms such as fatigue, post-exertional malaise, and cognitive dysfunction that last for months and impact everyday functioning, is referred to as Long COVID under the general category of post-acute sequelae of SARS-CoV-2 infection (PASC). PASC is highly heterogenous and may be associated with multisystem tissue damage/dysfunction including acute encephalitis, cardiopulmonary syndromes, fibrosis, hepatobiliary damages, gastrointestinal dysregulation, myocardial infarction, neuromuscular syndromes, neuropsychiatric disorders, pulmonary damage, renal failure, stroke, and vascular endothelial dysregulation. A better understanding of the pathophysiologic mechanisms underlying PASC is essential to guide prevention and treatment. This review addresses potential mechanisms and hypotheses that connect SARS-CoV-2 infection to long-term health consequences. Comparisons between PASC and other virus-initiated chronic syndromes such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome will be addressed. Aligning symptoms with other chronic syndromes and identifying potentially regulated common underlining pathways may be necessary for understanding the true nature of PASC. The discussed contributors to PASC symptoms include sequelae from acute SARS-CoV-2 injury to one or more organs, persistent reservoirs of the replicating virus or its remnants in several tissues, re-activation of latent pathogens such as Epstein–Barr and herpes viruses in COVID-19 immune-dysregulated tissue environment, SARS-CoV-2 interactions with host microbiome/virome communities, clotting/coagulation dysregulation, dysfunctional brainstem/vagus nerve signaling, dysautonomia or autonomic dysfunction, ongoing activity of primed immune cells, and autoimmunity due to molecular mimicry between pathogen and host proteins. The individualized nature of PASC symptoms suggests that different therapeutic approaches may be required to best manage specific patients.